Professional Essentials · True Rheumatic Emergencies · Free · No registration
Macrophage activation syndrome & secondary HLH
Recognize progressive hyperinflammation, search for its driver and treat organ threat before the diagnostic picture is complete.
1. Recognize the changing inflammatory pattern
Macrophage activation syndrome (MAS) is hemophagocytic lymphohistiocytosis (HLH) arising in a rheumatic inflammatory setting, particularly Still’s disease or lupus. Secondary HLH also accompanies infection and malignancy. These categories overlap: an infection can trigger MAS, and a presumed rheumatic flare may conceal lymphoma. The useful bedside question is whether uncontrolled inflammation is producing progressive organ injury.
Connect persistent fever, rising ferritin, falling blood counts, hepatitis and coagulopathy. Compare dated measurements with the patient’s own baseline. A platelet count that has fallen markedly from inflammatory thrombocytosis may be concerning while still within the reference interval. Declining fibrinogen and increasing AST can likewise reveal deterioration before conventional thresholds are crossed.
Shock, increasing oxygen requirement, encephalopathy, major bleeding or rapidly worsening organ function require critical-care escalation. Suspected evolving MAS/HLH needs urgent hospital assessment with hematology, rheumatology and infectious diseases. Do not wait for marrow hemophagocytosis, a complete score or a send-away immune assay before treating an organ threat.
Recognition and laboratory trajectory → Professional access required
2. Use diagnostic frameworks without letting them delay care
Ferritin is a useful signal but is not specific for HLH. Severe infection, liver injury, malignancy and other inflammatory conditions can produce substantial elevations. An isolated high value does not establish the syndrome, and an initially modest value cannot resolve a deteriorating clinical picture. Repeat measurements in the context of treatment and timing.
HLH-2004 originated in a pediatric diagnostic and treatment framework. The HScore was developed in a retrospective adult cohort. The 2016 MAS criteria classify disease in febrile patients with known or suspected systemic juvenile idiopathic arthritis. These frameworks can organize evidence; they are not interchangeable universal rule-out tests. Missing measurements must remain unknown rather than being entered as normal.
Absence of marrow hemophagocytosis does not exclude HLH, and its presence does not identify the driver. Marrow or tissue examination may instead be crucial for finding malignancy or infection. Coordinate sampling with hematology, particularly when glucocorticoids could reduce diagnostic yield, while preserving the priority of lifesaving treatment.
Criteria, marrow findings and masked presentations → Professional access required
3. Investigate the driver while supporting organs
Assess circulation, respiratory support, mental state, bleeding and urine output. Obtain blood count with differential and smear, ferritin, kidney and liver tests, LDH, coagulation profile, fibrinogen and triglycerides. Record specimen times, transfusion and treatment exposure. Urgent assessment does not need to wait for a fasting triglyceride sample.
Investigate infection according to the host, exposure and organ pattern, including cultures and targeted viral testing when relevant. EBV and CMV may be important; so may bacterial, fungal or parasitic disease. Add soluble IL-2 receptor and specialist immune or genetic testing when indicated and available. Their turnaround must not dictate the pace of stabilization.
Look actively for malignancy, especially lymphoma, and for alternative or coexisting explanations such as thrombotic microangiopathy, DIC, acute liver failure and drug toxicity. New seizures or encephalopathy demand urgent assessment; lumbar puncture is not automatic in an unstable or coagulopathic patient.
The April 2026 GIRFT pathway emphasizes coordinated assessment and specialist escalation. Name the lead clinician and assign ownership of pending investigations so diagnostic work continues after the first treatment is given.
Initial workup and disposition → Professional access required
4. Choose treatment for the driver and severity
The EULAR/ACR early HLH/MAS points support considering immunomodulation alongside ongoing diagnostic evaluation in probable progressive disease. Treatment of serious infection and hyperinflammation may be required simultaneously. Neither “sepsis” nor “MAS” should become a label that prevents reassessment of the other process.
For rheumatic MAS, high-dose glucocorticoids are central, with early additional treatment selected for severity and response. EULAR/PReS Still’s recommendations include IL-1 inhibition, ciclosporin and interferon-γ inhibition among the MAS options. Anakinra is widely used in this setting, but MAS treatment and intravenous administration are off-label in the United States. Kidney function affects its clearance; intensive-care dosing requires specialist and pharmacy review.
Ciclosporin introduces nephrotoxicity, hypertension, neurotoxicity and interaction concerns. IVIG may help selected patients but is not adequate sole rescue for progressive severe HLH; fluid burden, kidney injury, thrombosis and hemolysis risks affect suitability.
Severe EBV-associated, malignancy-associated or refractory HLH may require an etoposide-containing strategy. The adult HLH recommendations emphasize tailoring the regimen; applying a full pediatric protocol automatically to every adult can cause harm. Cytopenias may be a manifestation of untreated disease and do not by themselves settle whether etoposide should be withheld.
Trigger-specific treatment decisions → Professional access required
5. Recognize indication-specific options and safety
Emapalumab has a distinct US indication for HLH/MAS in known or suspected Still’s disease when glucocorticoid response is inadequate, glucocorticoids are not tolerated, or MAS recurs. This does not establish efficacy for every form of adult secondary HLH. The March 2026 prescribing information has a different starting regimen for Still’s-associated MAS than for primary HLH; use the actual indication-specific protocol.
Interferon-γ blockade increases infection susceptibility. Evaluate tuberculosis risk and latent infection, assess relevant active infections and plan indicated prophylaxis. Monitor viral infection or reactivation, including CMV, and infusion reactions. Avoid live vaccines during treatment. A specialist team should coordinate these precautions with the urgency of controlling MAS.
Cytokine blockade can also change recognition. A tocilizumab-treated pediatric cohort showed altered fever and laboratory expression during MAS. This supports caution with a low CRP or absent fever during IL-6 inhibition; it does not supply validated adult thresholds. Document the immunomodulator and last dose whenever the inflammatory picture appears unexpectedly quiet.
Treatment options and prescribing conditions → Professional access required
6. Judge response across physiology and laboratory trends
Follow oxygen and vasopressor needs, cognition, bleeding, urine output, blood counts, fibrinogen, liver tests and ferritin together. A falling ferritin is insufficient evidence of recovery when organ function or coagulation worsens. The GIRFT pathway includes daily laboratory surveillance; instability may require substantially more frequent bedside and laboratory reassessment.
Persistent deterioration should reopen the trigger search, drug exposure and adequacy of therapy. Infection can emerge during immunosuppression, and a response in one organ may coexist with progression elsewhere. Specify when treatment will be reconsidered and who can authorize escalation. There is no universal percentage ferritin decline that can replace this assessment.
After stabilization, complete evaluation of the underlying rheumatic disease, infection or malignancy and consider genetic assessment when the phenotype warrants it. Establish tapering, prophylaxis, toxicity monitoring and recurrence instructions. Plan early contact with an HLH-experienced center when local diagnostic or treatment resources are limited. Referral can proceed while antimicrobial and organ-support measures continue. In the recovery phase, distinguish recurrent hyperinflammation from infection or drug toxicity before restarting a previous regimen solely because ferritin has risen.
Communicate pending tissue, immune and microbiology results to the follow-up team. The handoff should preserve dated trends and actual treatment doses, not merely the label “HLH improving.”
Monitoring and escalation → Professional access required
Selected sources
- EULAR/ACR early HLH/MAS points,2022,published2023.
- EULAR/PReS Still’s disease recommendations,2024.
- La Rosée et al. Adult HLH recommendations,2019.
- Fardet et al. HScore development,2014.
- Shimizu et al. Tocilizumab and MAS features,2020.
- GIRFT HLH pathway,April2026.
- Gamifant US prescribing information,March2026.
Clinical review: October 4, 2026. This independent overview accompanies the full professional emergency module.